# PD-1 Antibody for Reactive EBV After BMT

> **NCT04690036** · EARLY_PHASE1 · UNKNOWN · sponsor: **Beijing Friendship Hospital** · enrollment: 20 (estimated)

## Conditions studied

- PD-1
- EBV Infection
- Transplant

## Interventions

- **DRUG:** toripalimab injection

## Key facts

- **NCT ID:** NCT04690036
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-01
- **Primary completion:** 2023-01-01
- **Final completion:** 2023-01-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04690036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04690036, "PD-1 Antibody for Reactive EBV After BMT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04690036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*